Enhancement of ACE and prolyl oligopeptidase inhibitory potency of protein hydrolysates from sardine and tuna by-products by simulated gastrointestinal digestion

This work was focused on the study of the bioactive potential of three fish protein hydrolysates, one of them prepared from industrial sardine by-products (heads and viscera) and the others from tuna by-products (heads, and muscle and viscera). These protein hydrolysates exhibited moderate ability t...

Descripción completa

Detalles Bibliográficos
Autores: Martínez Álvarez, Óscar, Batista, Irineu, Ramos, Cristina, Montero García, Pilar
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2016
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/178378
Acceso en línea:http://hdl.handle.net/10261/178378
Access Level:acceso abierto
Palabra clave:Hypertension
Fish waste
Angiotensin converting enzyme
Prolyl oligopeptidase
Descripción
Sumario:This work was focused on the study of the bioactive potential of three fish protein hydrolysates, one of them prepared from industrial sardine by-products (heads and viscera) and the others from tuna by-products (heads, and muscle and viscera). These protein hydrolysates exhibited moderate ability to inhibit Angiotensin Converting Enzyme (IC50 between 0.24-1.16 mg dry weight/ml) and Prolyl Oligopeptidase (IC50 between 3.30-9.57 mg/ml), being those obtained from tuna by-products the most effective. Overall, ACE- and PO-inhibiting activities were enhanced by sequential nanofiltration through 3 and 1 kDa MWCO membranes (IC50 between 0.02-0.16 mg/ml (ACE) and 1.10-4.21 mg/ml (PO)). The inhibitory properties of the hydrolysates were greatly improved by in vitro gastric digestion, and were barely affected by further intestinal digestion. The digested tuna hydrolysates proved to be the best source of PO- and ACE- inhibiting molecules (mainly that from heads (IC50 = 0.16 mg/ml (ACE) and 1.04 mg/ml (PO)) and could be potential new ingredients in food with interest in the prevention or treatment of cardiovascular and neurological diseases.